A
21.70
-0.35 (-1.59%)
| Penutupan Terdahulu | 22.05 |
| Buka | 22.40 |
| Jumlah Dagangan | 1,944,424 |
| Purata Dagangan (3B) | 2,808,155 |
| Modal Pasaran | 2,745,597,184 |
| Harga / Pendapatan (P/E TTM) | 60.28 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.30 |
| Harga / Jualan (P/S) | 2.51 |
| Harga / Buku (P/B) | 6.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Feb 2026 |
| Margin Keuntungan | -28.83% |
| Margin Operasi (TTM) | -49.96% |
| EPS Cair (TTM) | -1.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 285.94% |
| Nisbah Semasa (MRQ) | 4.08 |
| Aliran Tunai Operasi (OCF TTM) | -8.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 45.63 M |
| Pulangan Atas Aset (ROA TTM) | -14.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -103.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Apellis Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
-1.3
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.25 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.69% |
| % Dimiliki oleh Institusi | 104.60% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (HC Wainwright & Co., 121.20%) | Beli |
| 48.00 (Stifel, 121.20%) | Beli | |
| Median | 28.00 (29.03%) | |
| Rendah | 18.00 (Wedbush, -17.05%) | Pegang |
| Purata | 31.42 (44.79%) | |
| Jumlah | 8 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 21.48 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 05 Mar 2026 | 37.00 (70.51%) | Beli | 20.15 |
| Mizuho | 05 Mar 2026 | 20.00 (-7.83%) | Pegang | 20.15 |
| Citigroup | 25 Feb 2026 | 44.00 (102.76%) | Beli | 21.42 |
| HC Wainwright & Co. | 25 Feb 2026 | 48.00 (121.20%) | Beli | 21.42 |
| RBC Capital | 25 Feb 2026 | 21.00 (-3.23%) | Pegang | 21.42 |
| Wedbush | 25 Feb 2026 | 18.00 (-17.05%) | Pegang | 21.42 |
| Barclays | 28 Jan 2026 | 24.00 (10.60%) | Pegang | 23.07 |
| B of A Securities | 21 Jan 2026 | 28.00 (29.03%) | Beli | 20.95 |
| Wells Fargo | 20 Jan 2026 | 26.00 (19.82%) | Beli | 20.47 |
| Cantor Fitzgerald | 13 Jan 2026 | 35.00 (61.29%) | Beli | 21.33 |
| Needham | 13 Jan 2026 | 28.00 (29.03%) | Beli | 21.33 |
| Stifel | 19 Dec 2025 | 48.00 (121.20%) | Beli | 24.65 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 |
| 12 Jan 2026 | Pengumuman | Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |